High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda.

PubWeight™: 1.26‹?› | Rank: Top 10%

🔗 View Article (PMC 3840403)

Published in Clin Infect Dis on September 18, 2013

Authors

Caroline E Mullis1, Oliver Laeyendecker, Steven J Reynolds, Ponsiano Ocama, Jeffrey Quinn, Iga Boaz, Ronald H Gray, Gregory D Kirk, David L Thomas, Thomas C Quinn, Lara Stabinski

Author Affiliations

1: Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore.

Articles citing this

Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18

Seroprevalence for Hepatitis E and Other Viral Hepatitides among Diverse Populations, Malawi. Emerg Infect Dis (2015) 0.89

Hepatitis C in sub-saharan Africa: urgent need for attention. Open Forum Infect Dis (2014) 0.88

HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infect Dis (2016) 0.84

Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa). PLoS One (2015) 0.80

Absence of Active Hepatitis C Virus Infection in Human Immunodeficiency Virus Clinics in Zambia and Mozambique. Open Forum Infect Dis (2016) 0.77

Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. J Int AIDS Soc (2016) 0.77

Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. BMC Infect Dis (2017) 0.75

Reexamination of the relationship between the prevalence of hepatitis C virus and parenteral antischistosomal therapy among Egyptians resident in Qatar. Clin Exp Gastroenterol (2014) 0.75

A Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000-2013. BMC Infect Dis (2016) 0.75

PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort. Wellcome Open Res (2017) 0.75

Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study. J Int AIDS Soc (2017) 0.75

Articles by these authors

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99

Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59

Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22

Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83

Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97

Protection against persistence of hepatitis C. Lancet (2002) 5.94

The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol (2006) 5.41

Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 5.07

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54

Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54

Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51

Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33

Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27

HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24

The medical benefits of male circumcision. JAMA (2011) 4.05

Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med (2010) 3.84

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76

The effect of male circumcision on sexual satisfaction and function, results from a randomized trial of male circumcision for human immunodeficiency virus prevention, Rakai, Uganda. BJU Int (2008) 3.73

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53

Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ (2007) 3.41

Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS (2005) 3.39

Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30

Influence of HLA-C expression level on HIV control. Science (2013) 3.27

Hepatitis C and progression of HIV disease. JAMA (2002) 3.15

Age differences in sexual partners and risk of HIV-1 infection in rural Uganda. J Acquir Immune Defic Syndr (2003) 3.11

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06

HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03

IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02

In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01

Child mortality associated with reasons for non-breastfeeding and weaning: is breastfeeding best for HIV-positive mothers? AIDS (2003) 3.00

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00

Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99

A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol (2006) 2.91

The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS Med (2008) 2.79

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis (2003) 2.72

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71

Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61